The development of immunotherapies for non-small cell lung cancer

Bibliography

• GREENLEE RT, HILL-HARMON MB, MURRAY T, THUN M: Cancer statistics, 2001. CA Cancer J. OM. (2001) 51:15–36.
   PubMed Web of Science ®Google Scholar
• FIGLIN RA, CAMERON RB, TURRISI AT III: Non-small cell lung cancer. In: Cancer Treatment Haskell CM (Ed.), WB Saunders, Philadelphia, USA (2000) 36:598–628.
   Google Scholar
• •Excellent overview of the biology of the disease as well as numerous standard and experimental treatment options.
   Google Scholar
• BURNET FM: Immunological surveillance in neoplasia. Transplant Rev (1971) 7:3–25.
   PubMedGoogle Scholar
• BURNET FM: Immunological aspects of malignant disease. Lancet (1967) 1:1171–1174.
   PubMed Web of Science ®Google Scholar
• ••Fundamental concept in the field of tumour biology and immunology that still resonates with us today.
   Google Scholar
• SCHIRRMACHER V: Tumor vaccine design: concepts, mechanisms, and efficacy testing. mt. Arch. Allergy Immurrol (1995) 108:340–344.
   PubMed Web of Science ®Google Scholar
• HELLSTROM I, HELLSTROM KE: Tumor immunology: an overview. Ann. NY Acad. Sri. (1993) 690:24–33.
   PubMed Web of Science ®Google Scholar
• BOON T, VAN DER BRUGGEN P: Human tumor antigens recognized by T lymphocytes. J. Exp. Med. (1996) 183:725–729.
   PubMed Web of Science ®Google Scholar
• RESTIFO N, PSZNOL M: Cancer vaccines. In: Cancer: Principles & Practice of Oncology Devita VT Jr., Hellman S, Rosenberg SA (Eds) Lippincott-Raven Publishers, Philadelphia, USA (1997) 3023–3043.
   Google Scholar
• SHU S, PLAUTZ GE, KRAUSS JC, CHANG AE: Tumor immunology. JAMA (1997) 278:1972–1981.
   PubMed Web of Science ®Google Scholar
• WOJTOWICZ-PRAGA S: Reversal of tumor-induced immunosuppression: A new approach to cancer therapy. J. Immunother. (1997) 20:165–177.
   PubMed Web of Science ®Google Scholar
• BODMER WF, BROWNING MJ, KRAUSA P et al.: Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann. NY Acad. Sri. (1993) 690:42–49.
   PubMed Web of Science ®Google Scholar
• •One of the first papers to establish one key mechanism by which tumours avoid immune surveffiance.
   Google Scholar
• RESTIFO NP, ESQUIVEL E KAWAKAMI Y et al.: Identification of human cancers deficient in antigen processing. J. Exp. Med. (1993) 177:265–272.
   Google Scholar
• •One of the first papers to establish one key mechanism by which tumours avoid immune surveffiance.
   Google Scholar
• HICKLIN DJ, MARINCOLA FM, FERRONE S: HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med. Today (1999) 5:178–186.
   PubMedGoogle Scholar
• GABRILOVICH DI, CORAK J, CIERNIKIF, KAVANAUGH D, CARBONE DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. (1997) 3:483–490.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrated that APCs, and not only the T-cells they interact with and activate, can have defects potentially related to the tumour microenvirorunent.
   Google Scholar
• FINKE JH, ZEA AH, STANLEY J et al: Loss of T-cell receptor zeta chain and p56 lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. (1993) 53:5613–5616.
   PubMed Web of Science ®Google Scholar
• RUKAVINA D, LASKARIN G, RUBESA G et al.: Age-related decline of perforin expression in human cytotoxic T lymphocytes and natural killer cells. Blood (1998) 92:2410–2420.
   PubMed Web of Science ®Google Scholar
• EBERHARDT W, BILDAT S, KORFEE S: Combined modality therapy in NSCLC. Ann. Oricol (2000) 11:85–95.
   Web of Science ®Google Scholar
• MOUNTAIN CF: Revisions in the International System for Staging Lung Cancer. Chest (1997) 111:1710–1717.
   PubMed Web of Science ®Google Scholar
• JURETIC A, SOBAT H, SAMIJA M: Combined modality therapy of non-small cell lung cancers. Ann. Omni (1999) 10:93–98.
   Google Scholar
• MOUNTAIN CF: Surgery for stage IIIa-N2non-small cell lung cancer. Cancer (1994) 73:2589–2598.
   PubMed Web of Science ®Google Scholar
• GINSBERG RJ, HILL LD, EAGAN RT et al.: Modern thirty-day operative mortality for surgical resections in lung cancer. J. Thorac. Cardiovasc. Sorg. (1983) 86:654–658.
   PubMed Web of Science ®Google Scholar
• DARTEVELLE PG, CHAPELIER AR, MACCHIARINI P et al.: Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet. j Thorac. Cardiovasc. Surg. (1993) 105:1025–1034.
   PubMed Web of Science ®Google Scholar
• SAMIJA M, JURETIC A, ZIVKOVIC M et al.: Radiotherapy of lung cancer. Lijec. 1&esn. (1999) 121:358–366.
   Google Scholar
• KIRSH MM, SLOAN H: Mediastinal metastases in bronchogenic carcinoma: influence of postoperative irradiation, cell type, and location. Ann. Thorac. Surg. (1982) 33:459–463.
   PubMed Web of Science ®Google Scholar
• FIGLIN RA, PIANTADOSI S, FELD R: Intracranial recurrence of carcinoma after complete surgical resection of stage I, II, and III non-small-cell lung cancer. N Engl. Med. (1988) 318:1300–1305.
   PubMed Web of Science ®Google Scholar
• AWAN AM, WEICHSELBAUM RR: Palliative radiotherapy. Hernatol. Oricol. Clin. North Ara (1990) 4:1169–1181.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA: Chemotherapy for advanced non-small-cell lung cancer: modest progress, many choices. j Clin. Oricol. (2000) 18:35S–38S.
   Google Scholar
• •Good summary of current status of cytotoxic drugs for the treatment of NSCLC.
   Google Scholar
• BREATHNACH OS, FREIDLIN B, CONLEY B etal.: Twenty-two years of Phase III trials for patients with advanced non-small-cell lung cancer: sobering results. Clin. Oricol. (2001) 19:1734–1742.
   Google Scholar
• NO AUTHORS LISTED: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. Br Med. J (1995) 311:899–909.
   Google Scholar
• BITRAN J, DVOKES EE: Chemotherapyfor stage IV non-small cell lung cancer. Hernatol. Oricol. Clin. North Ara (1990) 4:1159–1168.
   PubMed Web of Science ®Google Scholar
• GRALLA RJ, CASPER ES, KELSEN DP et al.: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann. Intern. Med. (1981) 95:414–420.
   PubMed Web of Science ®Google Scholar
• LUEDKE DW, EINHORN L, OMURA GA et al.: Randomized comparison of two combination regimens versus minimal chemotherapy in non-small cell lung cancer: a Southeastern Cancer Study Group Trial. Oricol. (1990) 8:886–891.
   PubMed Web of Science ®Google Scholar
• BERTHELOT JM, WILL BP, EVANS WK et al.: Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. Nati Cancer Inst. (2000) 92:1321–1329.
   PubMed Web of Science ®Google Scholar
• KOSMAS C, TSAVARIS N, PANOPOULOS C etal.: Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens. Eur. Cancer (2001) 37:972–978.
   Google Scholar
• KOSMAS C, TSAVARIS NB, POLYZOS Aet al.: A Phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced non small cell lung carcinoma. Cancer (2000) 89:774–782.
   Google Scholar
• VAN CUTSEM E, TWELVES C, CASSIDY J et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin. Oricol. (2001) 19:4097–4106.
   PubMed Web of Science ®Google Scholar
• HIRSH V, LANGLEBEN A, AYOUB J et al.: Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic non small cell lung carcinoma: a Phase II multicenter trial. Cancer (2001) 92:830–835.
   PubMed Web of Science ®Google Scholar
• LILENBAUM RC, SCHWARTZ MA, SEIGEL L et al.: Phase II trial of weekly docetaxel in second-line therapy for non small cell lung carcinoma. Cancer (2001) 92:2158–2163.
   PubMed Web of Science ®Google Scholar
• ISLA D, ROSELL R, SANCHEZ JJ et al.: Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. Oricol. (2001) 19:1071–1077.
   PubMed Web of Science ®Google Scholar
• KHURI FR, RIGAS JR, FIGLIN RA et al.: Multi-institutional Phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin. Oricol. (2001) 19:2626–2637.
   PubMed Web of Science ®Google Scholar
• KLINGMAN RR, DEMEESTER TR: Surgical approach to non-small cell lung cancer stage I and II. Hernatol. Oncol. North Ain. (1990) 4:1079–1091.
   PubMed Web of Science ®Google Scholar
• BELANI CP, RAMANATHAN Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents. Chest (1998) 113:53S–60S.
   Google Scholar
• PISTERS KM: Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer. Semi]. Oricol. (2001) 28:23–28.
   PubMed Web of Science ®Google Scholar
• VOKES EE: Sequential combined modality therapy for stage III non-small cell lung cancer. Hernatol. Oricol. Clin. North Ara (1990) 4:1133–1142.
   PubMed Web of Science ®Google Scholar
• BONOMI P, REDDY S, FABER LP: Concurrent chemotherapy and thoracic irradiation in non-small cell lung cancer. Hernatol. Oricol. Clin. North Ain. (1990) 4:1143–1158.
   PubMed Web of Science ®Google Scholar
• SOCINSKI MA, ROSENMAN JG, HALLE J et al.: Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatinipaclitaxel in unresectable stage IIIA/B non small cell lung carcinoma: a modified Phase I/II trial. Cancer (2001) 92:1213–1223.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO: Monoclonal antibodies forthe treatment of cancer: principles and concepts. Cancer Invest. (2001) 19(8):833–841.
   PubMed Web of Science ®Google Scholar
• LARSON SM, DIVGI C, SGOUROS G, CHEUNG NV, SCHEINBERG DA (2000). Monoclonal antibodies: Basic principles. In: Principles and Practice of the Biologic Therapy of Cancer Rosenberg SA (Ed.) Lippincott Williams and Wilkins, Philadelphia, USA (2000) 1:396–412.
   Google Scholar
• •A great source of background information for this cancer treatment method.
   Google Scholar
• PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593–4599.
   Google Scholar
• LIN YS, NGUYEN C, MENDOZA JL etal.: Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. Phannacol. Exp. Ther. (1999) 288:371–378.
   Google Scholar
• GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. j Clin. Oricol. (2001) 19:843–850.
   PubMed Web of Science ®Google Scholar
• MARGOLIN K, GORDON MS, HOLMGREN E et al.: Phase lb trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. I Clin. Oricol. (2001) 19:851–856.
   PubMed Web of Science ®Google Scholar
• LONBERG N, HUSZAR D: Human antibodies from transgenic mice. Int. Rev Inunuriol. (1995) 13:65–93.
   PubMedGoogle Scholar
• LONBERG N, TAYLOR LD, HARDING FA etal.: Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature (1994) 368:856–859.
   Google Scholar
• ••The development of chimeric or fullyhuman antibodies revolutionised and revitalised a field whose clinical impact has been almost completely eroded by HAMA-related toxicities.
   Google Scholar
• MCDEVITT MR, SGOUROS G, FINN RD etal.: Radioimmunotherapy with alpha-emitting nuclides. Ear. j Nucl. Med. (1998) 25:1341–1351.
   Google Scholar
• FORD VA, STRINGER C, KENNEL SJ: Thrombomodulin is preferentially expressed in Balb/c lung microvessels.j. Biol. Chem. (1992) 267:5446–5450.
   PubMed Web of Science ®Google Scholar
• KENNEL SJ, BOLL R, STABIN M, SCHULLER HM, MIRZADEH S: Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi. Br I Cancer (1999) 80:175–184.
   PubMed Web of Science ®Google Scholar
• KENNEL SJ, CHAPPELL LL, DADACHOVA K et al.: Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors. Cancer Biother. Radiopharm. (2000) 15:235–244.
   PubMed Web of Science ®Google Scholar
• STEIN R, BASU A, GOLDENBERG DM,LLOYD KO, MATTES MJ: Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb R57. bit .j Cancer Suppl. (1994) 8:98–102.
   PubMedGoogle Scholar
• STEIN R, CHEN S, SHARKEY RIVI, GOLD ENBERG DM: Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: specificity and tumor targeting. Cancer Res. (1990) 50:1330–1336.
   PubMed Web of Science ®Google Scholar
• STEIN R, GOVINDAN SV, CHEN S et al.: Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody R57: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)1.1 Nucl. Med. (2001) 42:967–974.
   Google Scholar
• BREITZ HB, SULLIVAN K, NELP WB: Imaging lung cancer with radiolabeled antibodies. Serail]. Nucl. Med. (1993) 23:127–132.
   PubMed Web of Science ®Google Scholar
• DENARDO GL, O& DONNELL RT, DENARDO SJ: Status of radioimmunoimaging and radioimmunotherapy for cancer. Am. Soc. Chi]. Omni 1999 Spring Educ. Book (1999) 1:472–482.
   Google Scholar
• GREINER JW, ULLMANN CD, NIERODA C et al.: Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (1311-CC49) when given in combination with gamma-interferon. Cancer Res. (1993) 53:600–608.
   PubMed Web of Science ®Google Scholar
• GREINER JW, GUADAGNI E ROSELLI M, NIERODA CA: Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine. Anti-Cancer Res. (1996) 16:2129–2133.
   PubMed Web of Science ®Google Scholar
• MEREDITH RE BUESCHEN AJ, KHAZAELI MB et al.: Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. I Nucl. Med. (1994) 35:1017–1022.
   PubMed Web of Science ®Google Scholar
• SLOVIN SE SCHER HI, DIVGI CR etal.:Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res. (1998) 4:643–651.
   Google Scholar
• DISIS ML, CHEEVER MA: HER-2/neuoncogenic protein: issues in vaccine development. Crit. Rev Immurrol (1998) 18:37–45.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO: Unconjugated monoclonalantibodies for the treatment of hematologic and solid malignancies. Am. Soc. CBI]. Omni 1999 Spring Educ. Book (1999) 1:461–468.
   Google Scholar
• LIVINGSTON PO, WONG GY, ADLURI S et al: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. I Clin Omni (1994) 12:1036–1044.
   Google Scholar
• LIVINGSTON P: Ganglioside vaccines with emphasis on GM2. &vain. Omni (1998) 25:636–645.
   Google Scholar
• •A good background on the use of carbohydrate antigens in tumour vaccines.
   Google Scholar
• CHAPMAN PB, MORRISEY D, PANAGEAS KS et al.: Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin. Clin Cancer Res. (2000) 6:4658–4662.
   PubMed Web of Science ®Google Scholar
• WEIJTENS ME, WILLEMSEN RA, VAN KRIMPEN BA, BOLHUIS RL: Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int. I Cancer (1998) 77:181–187.
   PubMed Web of Science ®Google Scholar
• VISSERS JL, DE VRIES IJ, SCHREURS MW et al.: The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. (1999) 59:5554–5559.
   Google Scholar
• BASELGA J: New therapeutic agents targeting the epidermal growth factor receptor.j Clin Omni (2000) 18:54S–59S.
   Google Scholar
• BARGMANN CI, HUNG MC, WEINBERG RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (1986) 319:226-230. ccFrom the discovery of this oncogene hascome a vast amount of preclinical and clinical research using several approaches, and targeting almost every solid tumour.
   Google Scholar
• KLAPPER LN, KIRSCHBAUM MH, SELA MYARDEN Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. (2000) 77:25–79.
   PubMed Web of Science ®Google Scholar
• AGUS DB, AKITA RW, FOX WD et al: Apotential role for activated HER-2 in prostate cancer. Serail]. Omni (2000) 27:76-83. Discussion 92–100.
   Google Scholar
• WISECARVER JL: HER-2/neu testing comes of age. Am. I Chi]. Pathol (1999) 111:299-301. Editorial, comment.
   Google Scholar
• SCHNEIDER PM, HUNG MC, CHIOCCA SM et al: Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res. (1989) 49:4968–4971.
   PubMed Web of Science ®Google Scholar
• DAZZI H, HASLETON PS, THATCHER N etal.: Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br. Cancer (1989) 59:746–749.
   Google Scholar
• GILL GN, KAWAMOTO T, COCHET C et al.: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. I Biol. Chem. (1984) 259:7755–7760.
   Web of Science ®Google Scholar
• FAN Z, LU Y, WU X, MENDELSOHN J: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. I Biol. Chem. (1994) 269:27595–27602.
   Web of Science ®Google Scholar
• DIVGI CR, WELTS, KRIS M et al.: Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. I Natl. Cancel • Inst. (1991) 83:97–104.
   PubMed Web of Science ®Google Scholar
• BASELGA J, PFISTER D, COOPER MR et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. j Clin. °ma. (2000) 18:904–914.
   PubMed Web of Science ®Google Scholar
• YANG XD, JIA XC, CORVALAN JR, WANG E DAVIS CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev °ma. Hematol. (2001) 38:17–23.
   PubMed Web of Science ®Google Scholar
• KUAN CT, WIKSTRAND CJ, BIGNER DD: EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer (2001) 8:83–96.
   PubMed Web of Science ®Google Scholar
• CROMBET T, TORRES O, NENINGER E et al.: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Biother. Radiopharm. (2001) 16:93–102.
   PubMed Web of Science ®Google Scholar
• GONZALEZ GM, CROMBET T, TORRES F et al.: Epidermal growth factor based cancer vaccine for non small cell lung cancer therapy. Characterization of the obtained immune response and relation with improved survival. Proc. Am. Assoc. Clin. °ma. (2001) 20:273a. Abstract 1090.
   Google Scholar
• FORSBERG G, OHLSSON L, BRODIN T et al.: Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br I Cancer (2001) 85:129–136.
   PubMed Web of Science ®Google Scholar
• JABLONSKY MJ, SUBRAMANIAN PS, JOHNSON HM, RUSSELL JK, KRISHNA NR: The solution structure of a class II major histocompatibility complex superantigen binding domain. Biochem. Biophys. Res. Commun. (1997) 234:660–665.
   PubMed Web of Science ®Google Scholar
• LITTON MJ, DOHLSTEN M, HANSSON J et al: Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses. Am. j Pathol (1997) 150:1607–1618.
   PubMed Web of Science ®Google Scholar
• HOLZER U, ORLIKOWSKY T, ZEHRER C et al.: T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant. Immunology (1997) 90:74–80.
   PubMed Web of Science ®Google Scholar
• TOWNSEND SE, ALLISON JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (1993) 259:368–370.
   PubMed Web of Science ®Google Scholar
• FLEUREN GJ, GORTER A, KUPPEN PJK, LITVINOV S, WARNAAR SO: Tumor heterogeneity and immunotherapy of cancer. Immunol Rev (1995) 145:91–122.
   PubMed Web of Science ®Google Scholar
• CARBONE FR, BEVAN MJ: Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. Exp. Med. (1990) 171:377–387.
   PubMed Web of Science ®Google Scholar
• •One of the fundamental studies demonstrating key mechanisms in the cellular response to tumour.
   Google Scholar
• PARDOLL DM, TOPALIAN SL: The role of CD4+ T cell responses in antitumor immunity. Cum: Opin. Immunol (1998) 10:588–594.
   Google Scholar
• TOES RE, OSSENDORP E OFFRINGA R, MELIEF CJ: CD4 T cells and their role in antitumor immune responses. j Exp. Med. (1999) 189:753-756. Comment.
   Google Scholar
• GARRIDO E ALGARRA I: MHC antigensand tumor escape from immune surveillance. Adv. Cancer Res. (2001) 83:117–158.
   PubMed Web of Science ®Google Scholar
• KORKOLOPOULOU P, KAKLAMANIS L, PEZZELLA E HARRIS AL, GATTER KC: Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br. J. Cancer (1996) 73:148–153.
   PubMed Web of Science ®Google Scholar
• HOLLINSHEAD A, STEWART TH, TAKITA H, DALBOW M, CONCANNON J: Adjuvant specific active lung cancer immunotherapy trials. Tumor-associated antigens. Cancer (1987) 60:1249–1262.
   Google Scholar
• TAKITA H, HOLLINSHEAD AC, ADLER RH et al: Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: a 5-year survival analysis. I &mg. Oncol (1991) 46:9–14.
   Web of Science ®Google Scholar
• ROSENBERG SA, YANNELLI JR, YANG JC et al.: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. j Nat. Cancel • Inst. (1994) 86:1159–1166.
   PubMed Web of Science ®Google Scholar
• GOEDEGEBUURE PS, SPANJAARD RA, EBERLEIN TJ: T cells and tumor-infiltrating lymphocytes. Encyclopedia Cancer (1997) 3:1736–1750.
   Google Scholar
• MELIOLI G, RATTO GB, PONTE M et al.: Treatment of stage IIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. I Immunother. Emphasis Tumor Immunol (1996) 19:224–230.
   PubMed Web of Science ®Google Scholar
• RATTO GB, ZINO P, MIRABELLI S et al.: A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non small cell lung carcinoma. Cancer (1996) 78:244–251.
   PubMed Web of Science ®Google Scholar
• RATTO GB, CAFFERATA MA, SCOLARO T et al.: Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. j Immunother. (2000) 23:161–167.
   PubMed Web of Science ®Google Scholar
• CHANG AE, ARUGA A, CAMERON MJ et al.: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. j Clin. °ma. (1997) 15:796–807.
   PubMed Web of Science ®Google Scholar
• PLAUTZ GE, MILLER DW, BARNETT GH et al.: T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res. (2000) 6:2209–2218.
   PubMed Web of Science ®Google Scholar
• HIRAM A, ONO T, TANAKA M et al.: Generation of cytotoxic T lymphocytes against autologous lung cancer cells resistant to apoptosis. Anti-Cancer Res. (2001) 21:2561–2567.
   PubMed Web of Science ®Google Scholar
• ZITVOGEL L, ANGEVIN E, TURSZT: Dendritic cell-based immunotherapy of cancer. Ann. °ma. (2000) 11:199–205.
   Google Scholar
• BANCHEREAU J, SCHULER-THURNER B, PALUCKA AK, SCHULER G: Dendritic cells as vectors for therapy. Cell (2001) 106:271–274.
   PubMed Web of Science ®Google Scholar
• LANZAVECCHIA A, SALLUSTO F: Regulation of T cell immunity by dendritic cells. Cell (2001) 106:263–266.
   PubMed Web of Science ®Google Scholar
• MELLMAN I, STEINMAN RIVI: Dendritic cells: specialized and regulated antigen processing machines. Cell (2001) 106:255–258.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM, DHODAPKAR M: Active immunization against cancer with dendritic cells: the near future. hit. j Cancer (2001) 94:459–473.
   PubMed Web of Science ®Google Scholar
• WATTS C: Capture and processing of exogenous antigens for presentation on MHC molecules. Ann. Rev Immunol (1997) 15:821–850.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, CELLA M, DANIELI C, LANZAVECCHIA A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products. j Exp. Med. (1995) 182:389–400.
   PubMed Web of Science ®Google Scholar
• KHANNA R: Tumour surveillance: missing peptides and MHC molecules. Immunol. Cell Biol. (1998) 76:20–26.
   PubMed Web of Science ®Google Scholar
• SHURIN MR: Dendritic cells presenting tumor antigen. Cancer Immunol. Immunother. (1996) 43:158–164.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ NC, LOZIER A, FLAMENT C et al.: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. (1999) 5:405–411.
   PubMed Web of Science ®Google Scholar
• •Excellent report demonstrating the ability of dendritic cells to postively affect both non-MHC- and MHC-restricted cytotoxicity.
   Google Scholar
• SHURIN MR, GABRILOVICH DI: Regulation of dendritic cell system by tumor. Cancer Res. Ther. Control (2001) 11:65–78.
   Google Scholar
• GABRILOVICH DI, CHEN HL, GIRGIS KR et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. (1996) 2:1096–1103.
   PubMed Web of Science ®Google Scholar
• YANAGAWA H, TAKEUCHI E, SUZUKI Y et al.: Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol. Immunother. (1999) 48:396–400.
   PubMed Web of Science ®Google Scholar
• YANAGAWA H, TAKEUCHI E, SUZUKI Y et al.: Production of interleukin-10 by alveolar macrophages from lung cancer patients. Respir Med. (1999) 93:666–671.
   PubMed Web of Science ®Google Scholar
• SUZUKI Y, YANAGAWA H, NISHIOKA Y et al.: Efficient generation of dendritic cells from alveolar and pleural macrophages as well as blood monocytes in patients with lung cancer. Lung Cancer (2001) 34:195–205.
   PubMed Web of Science ®Google Scholar
• SALLUSTO E LANZAVECCHIA A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp. Med. (1994) 179:1109–1118.
   PubMed Web of Science ®Google Scholar
• SALGALLER ML: Prostate cancer immunotherapy at the dawn of the new millennium. Expert Opin Investig. Drugs (2000) 9:1217–1229.
   PubMed Web of Science ®Google Scholar
• GUNZER M, JANICH S, VARGA G, GRABBE S: Dendritic cells and tumor immunity. Sernin. Immunol. (2001) 13:291–302.
   Web of Science ®Google Scholar
• MEIDENBAUER N, ANDREESEN R, MACKENSEN A: Dendritic cells for specific cancer immunotherapy. Biol. Chem. (2001) 382:507–520.
   PubMed Web of Science ®Google Scholar
• NESTLE FO, BANCHEREAU J, HART D: Dendritic cells: On the move from bench to bedside. Nat. Med. (2001) 7:761–765.
   PubMed Web of Science ®Google Scholar
• HODGE JW: Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol. Immunother. (1996) 43:127–134.
   PubMed Web of Science ®Google Scholar
• ALTERS SE, GADEA JR, SORICH Met al.: Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. j Immunother. (1998) 21:17–26.
   Google Scholar
• FONG L, ENGLEMAN EG: Dendritic cells in cancer immunotherapy. Ann. Rev Immunol. (2000) 18:245–273.
   PubMed Web of Science ®Google Scholar
• PARDOLL DM: Paracrine cytokine adjuvants in cancer immunotherapy. Ann. Rev Immunol. (1995) 13:399–415.
   PubMed Web of Science ®Google Scholar
• TAYLOR JL, GROSSBERG SE: The effects of interferon-alpha on the production and action of other cytokines. Semi]. Oncol. (1998) 25:23–29.
   PubMed Web of Science ®Google Scholar
• GRECO FA, FIGLIN R, YORK M et al.: Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. Oncol. (1996) 14:2674–2681.
   Google Scholar
• KOSMIDIS PA, TSAVARIS N, SKARLOS D et al.: Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized Phase III trial. Hellenic Cooperative. j Clin. Oncol. (1996) 14:2682–2687.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. Nati Cancer Inst. (1997) 89:1616–1620.
   PubMed Web of Science ®Google Scholar
• KIRKWOOD JM: Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Eur. j Cancer (1998) 34\(Suppl. 3):512–517.
   Google Scholar
• BONIFAZI E DE VIVO A, ROSTI G et al.: Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 98:3074–3081.
   Google Scholar
• SALGALLER ML, LODGE PA: Use of cellular and cytokine adjuvants in the immunotherapy of cancer. j Surg. Oncol. (1998) 68:122–138.
   PubMed Web of Science ®Google Scholar
• AGARWALA SS: Interferon-alpha and - beta: clinical applications. In: Principles and Practice of the Biologic Therapy of Cancer. Rosenberg SA (Ed.) Lippincott Williams & Wilkins, Philadelphia, USA (2000) 1:275–285.
   Google Scholar
• CLARK SC, KAMEN R: The human hematopoietic colony-stimulating factors. Science (1987) 236:1229–1237.
   PubMed Web of Science ®Google Scholar
• METCALF D: The granulocyte-macrophage colony-stimulating factors. Science (1985) 229:16–22.
   PubMed Web of Science ®Google Scholar
• JONES T, STERN A, LIN R: Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant. Eur. Ora. ll/licrobiol. Infect. Dis. (1994) 13:S47–S53.
   PubMed Web of Science ®Google Scholar
• MARKOWICZ S, ENGLEMAN EG: Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. j Clin Invest. (1990) 85:955–961.
   PubMed Web of Science ®Google Scholar
• INABA K, INABA M, ROMANI N et al.: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/ macrophage colony-stimulating factor. Exp. Med. (1992) 176:1693–1702.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. Ora. Oncol. (1994) 12:2471–2508.
   Google Scholar
• AMAN MJ, STOCKDREHER K, THEWS A et al.: Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo. Ann. Hematol. (1996) 73:231–238.
   PubMed Web of Science ®Google Scholar
• SAMANCI A, YI Q, FAGERBERG J etal.: Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol. Immunother. (1998) 47:131–142.
   Google Scholar
• RINI BI, STADLER WM, SPIELBERGER RT, RATAIN MJ, VOGELZANG NJ: Granulocyte-macrophage-colony- stimulating factor in metastatic renal cell carcinoma: a Phase II trial. Cancer (1998) 82:1352–1358.
   PubMed Web of Science ®Google Scholar
• DUMMER R: GVAX (Cell Genesys). Cun: Opin. Investig. Drugs (2001) 2:844–848.
   PubMedGoogle Scholar
• SOIFFER R, LYNCHT, MIHM M et al.: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Nati Acad. Sci. USA (1998) 95:13141–13146.
   PubMed Web of Science ®Google Scholar
• SIMONS JW, MIKHAK B, CHANG JF et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59:5160–5168.
   PubMed Web of Science ®Google Scholar
• •The positive clinical results reported in this study could lead to the first genetically-modified tumour vaccine approved for clinical use.
   Google Scholar
• SIMONS JW, JAFFEE EM, WEBER CE et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. (1997) 57:1537–1546.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, STERMAN D, JABLONS D et al.: A Phase I/II study of autologous GM-CSF gene-modified cancer vaccines in subjects with non-small cell lung cancer. Proc. Am. Assoc. Chit. Omni (2001) 20:255a. Abstract 1019.
   Google Scholar
• MACH N, DRANOFF G: Cytokine-secreting tumor cell vaccines. Curr. Opin Immutiol. (2000) 12:571–575.
   PubMed Web of Science ®Google Scholar
• ZHANG SL, ZHANG HS, CORDON-CARDO C et al.: Selection of tumor antigens as targets for immune attack using immunohistochemistry. 2. Blood group-related antigens. Int. j Cancer (1997) 73:50–56.
   Google Scholar
• PARAJULI E YANAGAWA H, HANIBUCHI M et al.: Humanized anti-ganglioside GM2 antibody is effective to induce antibody-dependent cell-mediated cytotoxicity in mononuclear cells from lung cancer patients. Cancer Lett. (2001) 165:179–184.
   PubMed Web of Science ®Google Scholar
• ANTONIA SJ, SOTOMAYOR E: Gene therapy for lung cancer. Curr. Opin. Omni (2000) 12:138–142.
   PubMed Web of Science ®Google Scholar
• •Clear and concise overview of this approach to lung cancer treatment.
   Google Scholar
• RUBSAM LZ, BOUCHER PD, MURPHY PJ, KUKURUGA M, SHEWACH DS: Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus Type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. (1999) 59:669–675.
   PubMed Web of Science ®Google Scholar
• BI W, KIM YG, FELICIANO ES et al.: An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Ther. (1997) 4:246–252.
   PubMed Web of Science ®Google Scholar
• PASS HI, KALEMKERIAN G, BRIGHT RK: Novel molecular and immunotherapeutic strategies for lung cancer. Chest Surg. Clin. North Am. (2001) 11:189-2121x.
   Google Scholar
• ALMAND B, CARBONE DP: Biological considerations in lung cancer. Cancer Treat. Res. (2001) 105:1–30.
   PubMedGoogle Scholar
• WANG T, HOPKINS D, SCHMIDT C et al.: Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene (2000) 19:1519–1528.
   PubMed Web of Science ®Google Scholar
• KAWANO K, GOMI S, TANAKA K et al.: Identification of a new endoplasmic reticulum-resident protein recognized by HLA-A24-restricted tumor-infiltrating lymphocytes of lung cancer. Cancer Res. (2000) 60:3550–3558.
   PubMed Web of Science ®Google Scholar
• BRICHORY F, BEER D, LENAOUR E GIORDANO T, HANASH S: Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. (2001) 61:7908–7912.
   Google Scholar